Document
City of Seattle v. Purdue Pharma L.P. et al, 1:18-op-45089, No. 52 (N.D.Ohio May. 26, 2022)
Motion for Costs
Seattle recognizes that, exercising discretion, some courts have declined to award costs and fees when the removing party improperly invoked fraudulent misjoinder theory, but none confronted the aggravating circumstances here.
1 None endorsed it.
Cite Document
City of Seattle v. Purdue Pharma L.P. et al, 1:18-op-45089, No. 52 (N.D.Ohio May. 26, 2022)
+ More Snippets
Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3579 (N.D.Ohio Dec. 9, 2020)
“Track Three Cases” Over a year ago, on September 4, 2019, the Court issued an order ruling on “the Motion of Plaintiffs Cuyahoga and Summit Counties for Partial Summary Adjudication of their Equitable Claims for Abatement of an Absolute Public Nuisance.” See docket no. 2572 at 1 (“Nuisance SJ- Order”).
PageID #: 507622 depends on factual issues to be determined at trial,” and “denie[d] Plaintiffs’ motion to the extent it seeks a ruling that public nuisance liability is joint and several as a matter of law.” Id. at 6, 7.
The Pharmacy Defendants – apparently relying on the Court’s statement it would determine “at trial” whether their liability (if any) would be joint and several, or instead apportioned – have submitted proposed jury instructions for Track One-B addressing apportionment.
Thus, the Court, exercising its equitable powers, has the discretion to craft a remedy that will require Defendants, if they are found liable, to pay the prospective costs that will allow Plaintiffs’ to abate the opioid crisis.
See, e.g., id. at 8-9 (“While a bench trial may insulate litigants from the inflamed passions of a jury, there is also great virtue in entrusting the judgment of any case – especially one with such broad social significance – to the collective deliberation of twelve citizens representing a cross-section of society, properly instructed by the Court, rather than reposing the entire responsibility in the mind and sensibilities of just one individual.”).
Cite Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3579 (N.D.Ohio Dec. 9, 2020)
+ More Snippets
Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3499 (N.D.Ohio Sep. 22, 2020)
Laborers Health & Welfare Fund
PageID #: 502743 Davie v. Mitchell
Morris v. SullivanBolles v. Toledo Trust Co. Track Three OrderMorris Bolles See Track Three OrderMorris Bolles W. Kentucky Royalty Tr. v. Armstrong Coal Reserves, Inc
PageID #: 502745 all Track Three Order only
Track Three Order In re City of Memphis Adell v. Cellco P’ship United States v. Stone
Cite Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3499 (N.D.Ohio Sep. 22, 2020)
+ More Snippets
Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3362 (N.D.Ohio Jun. 30, 2020)
“[D]oubts regarding appealability [should be] resolved in favor of finding that the interlocutory order is not appealable.” Adell v. Cellco P’ship, No. 1:18cv623, 2019 WL 5285627, at *1 (N.D. Ohio Oct. 18, 2019) (quoting United States v. Stone, 53 F.3d 141, 143–44 (6th Cir. 1995)).
This Court previously considered and denied a similar request by Distributors to certify for interlocutory appeal the Court’s partial denial of their motion to dismiss Plaintiffs’ RICO claims in Cleveland Bakers & Teamsters Health & Welfare Fund et al. v. Purdue Pharma, L.P. et al, No. 18op45432.
3d 639, 644 (N.D. Ohio 2016) (citation omitted) (declining to certify appeal where defendant cited no precedent calling into question court’s interpretation of statute and failed to demonstrate difference of opinion within or among circuits).
As Distributors state, under Michigan law, “[t]he primary goal of judicial interpretation of statutes is to ascertain and give effect to the intent of the Legislature.
Instead, they argue reasonable jurists could disagree with the conclusion that Plaintiff’s claims are not based on “production of a product,” asserting Michigan courts interpret the MPLA’s immunity provisions “broadly.” In support, Distributors rely on cases describing legislative intent and the “myriad of activities” protected by the statute.
Cite Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3362 (N.D.Ohio Jun. 30, 2020)
+ More Snippets
Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3318 (N.D.Ohio Jun. 3, 2020)
Cite Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3318 (N.D.Ohio Jun. 3, 2020)
+ More Snippets
Document
City of Seattle v. Purdue Pharma L.P. et al, 1:18-op-45089, No. 54 (N.D.Ohio Jun. 23, 2022)
Case: 1:18-op-45089-DAP Doc #: 54 Filed: 06/23/22 1 of 1. PageID #: 1461
Cite Document
City of Seattle v. Purdue Pharma L.P. et al, 1:18-op-45089, No. 54 (N.D.Ohio Jun. 23, 2022)
+ More Snippets
Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3284 (N.D.Ohio Apr. 30, 2020)
Cite Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3284 (N.D.Ohio Apr. 30, 2020)
+ More Snippets
Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3285 (N.D.Ohio Apr. 30, 2020)
Cite Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3285 (N.D.Ohio Apr. 30, 2020)
+ More Snippets
Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3265 (N.D.Ohio Apr. 20, 2020)
Cite Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3265 (N.D.Ohio Apr. 20, 2020)
+ More Snippets
Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3243 (N.D.Ohio Mar. 27, 2020)
Cite Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3243 (N.D.Ohio Mar. 27, 2020)
+ More Snippets
Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3164 (N.D.Ohio Feb. 11, 2020)
Cite Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3164 (N.D.Ohio Feb. 11, 2020)
+ More Snippets
Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3101 (N.D.Ohio Jan. 27, 2020)
Cite Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3101 (N.D.Ohio Jan. 27, 2020)
+ More Snippets
Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3089 (N.D.Ohio Jan. 21, 2020)
Cite Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3089 (N.D.Ohio Jan. 21, 2020)
+ More Snippets
Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3078 (N.D.Ohio Jan. 14, 2020)
Cite Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 3078 (N.D.Ohio Jan. 14, 2020)
+ More Snippets
Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 2983 (N.D.Ohio Dec. 12, 2019)
Cite Document
In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 2983 (N.D.Ohio Dec. 12, 2019)
+ More Snippets